[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652894":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Kaiser Permanente","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SCALED Cohort",null,"The SCALED Cohort will include \\~500 participants from the REFOCUS-HTN Cohort who are KPNC health plan members aged 18 years or older with established hypertension diagnosed within the past 18 months prior to screening.",[13],"Other: observational study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"observational study","Participants are not assigned an intervention",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ankeet S Bhatt, MD, MBA, ScM","CONTACT","415-470-6571","Ankeet.S.Bhatt@kp.org",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Mirasol M Apostol-Largeteau, MPH","415-407-1754","Mirasol.M.Apostol-Largeteau@kp.org",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Kaiser Permanente Northern California","RECRUITING","Oakland","California","94611","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-122.2708,37.80437,{"lat":42,"lon":41},[45],{"name":46,"role":22,"phone":47,"phoneExt":10,"email":48},"Tiffany Chen","925-789-5363","tiffany.m.chen@kp.org",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":54},"AstraZeneca","INDUSTRY","100652894","refocus-htn-us-west-a-data-infrastructure-to-characterize-individuals-with-hypertension-100652894",false,"NCT07780500","REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension","REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing","REFOCUS-HTN","Inclusion Criteria:\n\nThe SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following:\n\n* ≥1 outpatient, non-emergency department diagnosis of hypertension;\n* ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart;\n* ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart.\n\nAdditional Eligibility Criteria for SCALED:\n\n* Hypertension diagnosis within the past 18 months prior to screening.\n* At least 6 months of continuous health plan coverage prior to initial visit.\n\nExclusion Criteria:\n\n* Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension;\n* Bariatric surgery or GLP1 prescription in the last 12 months;\n* Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks;\n* Last known estimated glomerular filtration rate \\\u003C 45 mL\u002Fmin\u002F1.73m2 (according to the CKD-EPI equation) at the time of screening;\n* Kidney transplant;\n* Currently receiving dialysis;\n* Current enrollment in any cardiovascular or blood pressure interventional trial.","ALL","18 Years",{"count":66,"type":67},500,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.",[72,73,74],"Hypertension","Aldosterone Disorder","Cardiovascular Disease (CVD)",[72,76,77,78,79],"Aldosterone","aldosterone dysregulation","aldosterone disorder","cardiovascular disease (CVD)","2026-08-14",{"date":82,"type":83},"2026-08-21","ACTUAL",{"date":85,"type":67},"2026-08-20",{"date":87,"type":67},"2029-03",{"name":5,"class":6},1]